EuroMOTOR is a European collaborative project (FP7) dedicated to discover new causative and disease modifying pathways to pave the way for novel therapies for Amyotrophic Lateral Sclerosis. The EuroMOTOR consortium is currently identifying/prioritizing the top 3-5 lead candidates identified in an integrated approach from the results of genomics studies, proteomics studies, metabolomics studies and high-throughput screening in motor neurons derived from iPS cells from ALS patients.
EuroMOTOR aims to strengthen the consortium by including an ambitious SME (biotech/pharma) that can contribute to one and/or a combination of the following tasks:
Identification of the most promising drugable compounds by defining their chemical structure
Production of analogues of the compounds
Determination of the structure-activity relationship (SAR) of the compounds
Determination of the compounds’ potential to cross the blood-brain barrier, solubility and pharmacokinetics
For more information and the application procedure, please go to www.euromotorproject.eu